miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Sunitinib is a multitargeting tyrosine kinase inhibitor used for metastatic renal cancer. There are no biomarkers that can predict sunitinib response. Such markers are needed to avoid administration of costly medication with side effects to patients who would not benefit from it. We compared global...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Ther
Главные авторы: Khella, Heba W Z, Butz, Henriett, Ding, Qiang, Rotondo, Fabio, Evans, Kenneth R, Kupchak, Peter, Dharsee, Moyez, Latif, Ashraf, Pasic, Maria D, Lianidou, Evi, Bjarnason, Georg A, Yousef, George M
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2015
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4817948/
https://ncbi.nlm.nih.gov/pubmed/26201448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2015.129
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы